Status:
COMPLETED
Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Growth Hormone Disorder
Growth Hormone Deficiency in Children
Eligibility:
All Genders
6+ years
Phase:
PHASE4
Brief Summary
This study is conducted in Europe. The aim of this study is to compare the easiness of use of Norditropin NordiFlex® device to the device previously used by patients or parents.
Eligibility Criteria
Inclusion
- Children who can receive Norditropin® (somatropin) treatment according to the product labelling
- Treated with growth hormone for at least one year
Exclusion
- Contraindications to Norditropin® growth hormone therapy
- Known or suspected hypersensitivity to somatropin or related products
- The receipt of any investigational medicinal product within 3 months prior to study start
- Life threatening disease, for example cancer
- Pregnancy or the intention of becoming pregnant
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT01245374
Start Date
November 1 2010
End Date
April 1 2011
Last Update
February 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Paris La Défense Cedex, France, 92932